EDDIE THARA D.O.
Prescription History 1932436821
Internal Medicine - Hematology & Oncology in Downey, CA


Quality Rating: 100 out of 100 score

NPI Status: Active since November 12, 2009

Contact Information

11480 BROOKSHIRE AVE
SUITE 309
DOWNEY, CA
ZIP 90241
Phone: (562) 869-1201
Fax: (562) 869-1281

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for EDDIE THARA D.O., an active Hematology & Oncology specialist practicing in Downey, CA. Our medical registry currently tracks 36 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 1,330 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 141 claims alone.


Abiraterone Acetate

Generic Formulation: Abiraterone AcetateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 96
30-Day Fills 96.0
Days Supply 2,880
CA State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills51.1
Peer Average Days Supply1,527
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 100.0% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $508,254.25 across this reporting matrix range.

Provider Avg Cost Per Claim

$5,294.32

State Avg Cost Per Claim

$1,946.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.

Therapeutic Applications

This medication is used to treat prostate cancer. Abiraterone belongs to a class of drugs known as anti-androgens (anti-testosterone). Testosterone, a natural hormone, helps prostate cancer to grow and spread. Abiraterone works by blocking the production of testosterone, thereby slowing the growth and spread of prostate cancer. This medication should not be given to women or children.

Alendronate Sodium

Generic Formulation: Alendronate SodiumSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 31.8
Days Supply 952
CA State Average Benchmarks
Peer Average Claims58.0
Peer Average 30-Day Fills138.0
Peer Average Days Supply4,109
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 79.3% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $91.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.65

State Avg Cost Per Claim

$12.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Therapeutic Applications

Alendronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss. This effect helps maintain strong bones and reduce the risk of broken bones (fractures). Alendronate belongs to a class of drugs called bisphosphonates.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 141
30-Day Fills 349.0
Days Supply 10,470
CA State Average Benchmarks
Peer Average Claims68.0
Peer Average 30-Day Fills165.7
Peer Average Days Supply4,950
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 107.4% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,502.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$39.03

State Avg Cost Per Claim

$27.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Bortezomib

Generic Formulation: BortezomibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 280
CA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.7
Peer Average Days Supply409
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,092.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$622.52

State Avg Cost Per Claim

$2,558.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as multiple myeloma, mantle cell lymphoma). It works by slowing or stopping the growth of cancer cells.

Carboplatin

Generic Formulation: CarboplatinSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 24
30-Day Fills 24.2
Days Supply 562
CA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.8
Peer Average Days Supply633
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,355.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$56.47

State Avg Cost Per Claim

$56.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An organoplatinum compound that possesses antineoplastic activity.

Therapeutic Applications

Carboplatin is used to treat various types of cancer. It is a chemotherapy drug that contains platinum. It is used to slow or stop cancer cell growth.

Cisplatin

Generic Formulation: CisplatinSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.4
Days Supply 294
CA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.6
Peer Average Days Supply456
Conservative Utilization

This provider writes prescriptions for this formulation 35.0% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $667.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$51.36

State Avg Cost Per Claim

$61.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.

Therapeutic Applications

Cisplatin is used to treat various types of cancer. It is a chemotherapy drug that contains platinum. It is used to slow or stop cancer cell growth.

Cyclophosphamide

Generic Formulation: CyclophosphamideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 441
CA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.4
Peer Average Days Supply403
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,157.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$626.54

State Avg Cost Per Claim

$686.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Therapeutic Applications

Cyclophosphamide is used to treat various types of cancer. It is a chemotherapy drug that works by slowing or stopping cell growth. Cyclophosphamide also works by decreasing your immune system's response to various diseases. It is used to treat a certain type of kidney disease in children after other treatments have not worked.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 32
30-Day Fills 36.5
Days Supply 842
CA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills36.0
Peer Average Days Supply559
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $695.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.72

State Avg Cost Per Claim

$19.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Dexamethasone Sodium Phosphate

Generic Formulation: Dexamethasone Sodium PhosphateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 96
30-Day Fills 98.3
Days Supply 2,242
CA State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills55.6
Peer Average Days Supply1,350
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 100.0% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $282.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$2.94

State Avg Cost Per Claim

$26.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions. This injectable form of dexamethasone is used when a similar drug cannot be taken by mouth or when a very fast response is needed, especially in patients with severe medical conditions. Talk to your doctor about the risks and benefits of dexamethasone, especially if it is to be injected near your spine (epidural). Rare but serious side effects may occur with epidural use.

Diphenhydramine Hcl

Generic Formulation: Diphenhydramine HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 63
30-Day Fills 63.2
Days Supply 1,444
CA State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills31.9
Peer Average Days Supply547
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 103.2% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $208.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.31

State Avg Cost Per Claim

$29.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Diphenhydramine injection is an antihistamine used to treat life-threatening allergic reactions (anaphylaxis) along with epinephrine and other treatments. It is also used to relieve symptoms of household allergies, hay fever and the common cold when medication cannot be given by mouth. Common allergy symptoms relieved by antihistamines include rash, itching, watery eyes, itchy eyes/nose/throat, cough, runny nose and sneezing. It is also used to treat nausea, vomiting and dizziness caused by motion sickness when medication cannot be given by mouth. Diphenhydramine works by blocking a certain natural substance (histamine) that your body makes during an allergic reaction. Its drying effects on such symptoms as watery eyes and runny nose are caused by blocking another natural substance made by your body (acetylcholine). Diphenhydramine should not be used in newborns or premature infants because of an increased risk of side effects. It should not be used for common cold symptoms in children less than 6 years of age due to the risk of serious side effects, such as slow/shallow breathing. Cough-and-cold products have not been shown to be safe or effective in children younger than 6.

Doxorubicin Hcl

Generic Formulation: Doxorubicin HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 399
CA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.0
Peer Average Days Supply364
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $711.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$37.44

State Avg Cost Per Claim

$57.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Doxorubicin is an anthracycline type of chemotherapy that is used to treat several different types of cancer. Doxorubicin works by slowing or stopping the growth of cancer cells.

Eliquis

Generic Formulation: ApixabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 90
30-Day Fills 150.0
Days Supply 4,477
CA State Average Benchmarks
Peer Average Claims68.0
Peer Average 30-Day Fills112.8
Peer Average Days Supply3,201
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 32.4% more claims than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $84,091.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$934.35

State Avg Cost Per Claim

$848.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Famotidine

Generic Formulation: Famotidine/PfSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 66
30-Day Fills 67.9
Days Supply 1,569
CA State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills52.2
Peer Average Days Supply1,044
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 29.4% more claims than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $99.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$1.50

State Avg Cost Per Claim

$6.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

Therapeutic Applications

Famotidine is used to treat ulcers of the stomach and intestines and to prevent intestinal ulcers from coming back after they have healed. This medication is also used to treat certain stomach and throat (esophagus) problems (such as erosive esophagitis, gastroesophageal reflux disease-GERD, Zollinger-Ellison syndrome). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as cough that doesn't go away, stomach pain, heartburn, and difficulty swallowing. Famotidine belongs to a class of drugs known as H2 blockers. This medication is also available without a prescription. It is used to prevent and treat heartburn and other symptoms caused by too much acid in the stomach (acid indigestion). If you are taking this medication for self-treatment, it is important to read the manufacturer's package instructions carefully so you know when to consult your doctor or pharmacist.

Fosaprepitant Dimeglumine

Generic Formulation: Fosaprepitant DimeglumineSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 252
CA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.0
Peer Average Days Supply572
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.8% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $827.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$68.94

State Avg Cost Per Claim

$224.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Fosaprepitant is used with other medications to help prevent nausea and vomiting caused by cancer drug treatment (chemotherapy). Fosaprepitant works by blocking one of the body's natural substances (substance P/neurokinin 1) that causes vomiting. This medication will not treat nausea or vomiting that has already started. Ask your doctor what you should do if you already have nausea or vomiting.

Gemcitabine Hcl

Generic Formulation: Gemcitabine HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 322
CA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills31.1
Peer Average Days Supply776
Conservative Utilization

This provider writes prescriptions for this formulation 46.4% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,757.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$183.83

State Avg Cost Per Claim

$257.08

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Gemcitabine is used to treat certain types of cancer (including biliary tract, breast, lung, ovarian, pancreatic). It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 30
30-Day Fills 70.5
Days Supply 2,116
CA State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills69.5
Peer Average Days Supply2,062
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,196.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$39.89

State Avg Cost Per Claim

$42.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 540
CA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills24.4
Peer Average Days Supply728
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $154,485.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$8,582.52

State Avg Cost Per Claim

$1,586.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Keytruda

Generic Formulation: PembrolizumabSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 429
CA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills28.2
Peer Average Days Supply606
Conservative Utilization

This provider writes prescriptions for this formulation 25.9% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $228,204.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$11,410.21

State Avg Cost Per Claim

$11,737.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pembrolizumab is used to treat cancer. It works by changing the action of your own immune system, directing it to attack cancer cells. Pembrolizumab belongs to a class of drugs known as monoclonal antibodies.

Lenalidomide

Generic Formulation: LenalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 273
CA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.3
Peer Average Days Supply700
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $126,950.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$9,765.45

State Avg Cost Per Claim

$12,446.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Letrozole

Generic Formulation: LetrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 28
30-Day Fills 69.2
Days Supply 2,077
CA State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills111.8
Peer Average Days Supply3,337
Conservative Utilization

This provider writes prescriptions for this formulation 41.7% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,312.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$46.89

State Avg Cost Per Claim

$32.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Lupron Depot

Generic Formulation: Leuprolide AcetateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 26
30-Day Fills 78.0
Days Supply 2,340
CA State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills69.3
Peer Average Days Supply2,064
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $149,043.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$5,732.45

State Avg Cost Per Claim

$4,304.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.

Therapeutic Applications

Leuprolide is used to treat advanced prostate cancer. It is not a cure. Most types of prostate cancer need the hormone testosterone to grow and spread. Leuprolide works by reducing the amount of testosterone that the body makes. This helps slow or stop the growth of cancer cells and helps relieve symptoms such as painful/difficult urination. Talk to your doctor about the risks and benefits of treatment.

Magnesium Sulfate

Generic Formulation: Magnesium SulfateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.4
Days Supply 294
CA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills22.0
Peer Average Days Supply247
Conservative Utilization

This provider writes prescriptions for this formulation 38.1% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $39.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.03

State Avg Cost Per Claim

$31.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083)

Mvasi

Generic Formulation: Bevacizumab-AwwbSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 483
CA State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills47.6
Peer Average Days Supply1,092
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.1% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $147,821.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$6,427.00

State Avg Cost Per Claim

$6,594.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-VEGF humanized murine monoclonal antibody. It inhibits VEGF RECEPTORS and helps to prevent PATHOLOGIC ANGIOGENESIS.

Therapeutic Applications

This medication is a man-made antibody (IgG1) used to treat various types of cancer. This drug works by blocking a certain protein (vascular endothelial growth factor-VEGF) thereby decreasing the blood supply to the tumor and slowing tumor growth. This monograph is about the following bevacizumab products: bevacizumab, bevacizumab-awwb, bevacizumab-bvzr, and bevacizumab-maly.

Ondansetron Hcl

Generic Formulation: Ondansetron Hcl/PfSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 89
30-Day Fills 91.1
Days Supply 2,039
CA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills30.5
Peer Average Days Supply570
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 196.7% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $140.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$1.58

State Avg Cost Per Claim

$8.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Ondansetron Odt

Generic Formulation: OndansetronSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 48
30-Day Fills 48.0
Days Supply 560
CA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills23.3
Peer Average Days Supply245
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 118.2% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $695.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.49

State Avg Cost Per Claim

$21.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. Ondansetron works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Oxaliplatin

Generic Formulation: OxaliplatinSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 42
30-Day Fills 42.0
Days Supply 903
CA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.2
Peer Average Days Supply678
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 50.0% more claims than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,410.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$105.01

State Avg Cost Per Claim

$295.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane, and with an oxalate ligand which is displaced to yield active oxaliplatin derivatives. These derivatives form inter- and intra-strand DNA crosslinks that inhibit DNA replication and transcription. Oxaliplatin is an antineoplastic agent that is often administered with FLUOROURACIL and FOLINIC ACID in the treatment of metastatic COLORECTAL NEOPLASMS.

Therapeutic Applications

This medication is used to treat advanced cancer of the colon and rectum. Oxaliplatin is a chemotherapy drug that contains platinum. It is used to slow or stop cancer cell growth.

Paclitaxel

Generic Formulation: PaclitaxelSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.2
Days Supply 471
CA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills21.8
Peer Average Days Supply513
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,160.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$108.01

State Avg Cost Per Claim

$141.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.

Therapeutic Applications

Paclitaxel is used to treat various types of cancer. It is a cancer chemotherapy drug that works by slowing or stopping cancer cell growth.

Palonosetron Hcl

Generic Formulation: Palonosetron HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.2
Days Supply 287
CA State Average Benchmarks
Peer Average Claims78.0
Peer Average 30-Day Fills78.8
Peer Average Days Supply1,820
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 83.3% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $560.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$43.11

State Avg Cost Per Claim

$106.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy). It is also used to prevent nausea and vomiting after surgery. Palonosetron works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Prednisone

Generic Formulation: PrednisoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 116
30-Day Fills 132.1
Days Supply 3,491
CA State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills52.2
Peer Average Days Supply1,075
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 190.0% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,000.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.63

State Avg Cost Per Claim

$8.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Ruxience

Generic Formulation: Rituximab-PvvrSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 16.7
Days Supply 406
CA State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills14.7
Peer Average Days Supply343
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $85,412.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$5,694.13

State Avg Cost Per Claim

$6,564.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Rituximab is used to treat certain types of cancer (such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia). It works by slowing or stopping the growth of cancer cells. Some brands of rituximab are also used to treat rheumatoid arthritis and can decrease joint pain and swelling. This drug is also used to treat certain types of blood vessel disease (such as granulomatosis with polyangiitis, microscopic polyangiitis) and can decrease the swelling of the blood vessels. Rituximab is also used to treat a certain skin condition (pemphigus vulgaris). It helps to reduce the number of skin lesions. This monograph is about the following rituximab products: rituximab, rituximab-abbs, rituximab-arrx, and rituximab-pvvr.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 35.2
Days Supply 1,057
CA State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills83.0
Peer Average Days Supply2,479
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.8% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $787.92 across this reporting matrix range.

Provider Avg Cost Per Claim

$60.61

State Avg Cost Per Claim

$36.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Tecentriq

Generic Formulation: AtezolizumabSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 462
CA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills21.5
Peer Average Days Supply459
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $223,549.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$10,161.35

State Avg Cost Per Claim

$10,654.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat various cancers (such as liver/lung/skin cancer, alveolar soft part sarcoma - ASPS). It works by helping your immune system fight the cancer. Atezolizumab belongs to a class of drugs known as monoclonal antibodies.

Vincristine Sulfate

Generic Formulation: Vincristine SulfateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 231
CA State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills13.3
Peer Average Days Supply280
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $109.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.91

State Avg Cost Per Claim

$9.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)

Therapeutic Applications

Vincristine is used to treat various types of cancer. It is a cancer chemotherapy drug that is usually used with other chemotherapy drugs to slow or stop cancer cell growth.

Zarxio

Generic Formulation: Filgrastim-SndzSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 24
30-Day Fills 24.0
Days Supply 470
CA State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.8
Peer Average Days Supply341
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $25,721.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,071.73

State Avg Cost Per Claim

$1,510.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A recombinant granulocyte colony-stimulating factor (G-CSF) that is used in the treatment and prevention of NEUTROPENIA, preparation and collection of blood progenitor cells, and for use in PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.

Therapeutic Applications

Filgrastim is a man-made version of a certain natural substance made by your body. It is used to help your body make more white blood cells. White blood cells are important to help you fight off infections. Filgrastim is given to people whose ability to make white blood cells is reduced (for instance, due to chemotherapy, chronic neutropenia, or exposure to large amounts of radiation). It is also used in certain treatment procedures (such as bone marrow/stem cell transplant). This monograph is about the following filgrastim products: filgrastim, tbo-filgrastim, filgrastim-sndz, filgrastim-aafi, and filgrastim-ayow.

Zirabev

Generic Formulation: Bevacizumab-BvzrSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 294
CA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills21.3
Peer Average Days Supply471
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $72,573.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$5,183.84

State Avg Cost Per Claim

$5,737.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is a man-made antibody (IgG1) used to treat various types of cancer. This drug works by blocking a certain protein (vascular endothelial growth factor-VEGF) thereby decreasing the blood supply to the tumor and slowing tumor growth. This monograph is about the following bevacizumab products: bevacizumab, bevacizumab-awwb, bevacizumab-bvzr, and bevacizumab-maly.

Zoledronic Acid

Generic Formulation: Zoledronic AcidSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 19
30-Day Fills 21.0
Days Supply 594
CA State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills20.5
Peer Average Days Supply597
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 46.2% more claims than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,234.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$170.26

State Avg Cost Per Claim

$168.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.

Therapeutic Applications

This medication is used to treat high blood calcium levels (hypercalcemia) that may occur with cancer. Zoledronic acid is also used with cancer chemotherapy to treat bone problems that may occur with multiple myeloma and other types of cancer (such as breast, lung) that have spread to the bones. Zoledronic acid belongs to a class of drugs known as bisphosphonates. It lowers high blood calcium levels by reducing the amount of calcium released from your bones into your blood. It also works by slowing the breakdown of your bones by cancer to prevent bone fractures.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like EDDIE THARA D.O. provides transparency into local medical care patterns within Downey, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.